JBJS - 2026-05-20 - Journal Article; Comparative Study
Postoperative Clopidogrel Thromboprophylaxis in TJA: Increased Risk of Transfusion but Similar Venous Thromboembolic Risk Compared with Aspirin.
Telang SS, Telang S, Palmer RC, Stronach BM, Stambough JB, Lieberman JR, Heckmann ND
Topics
Key Takeaway
Clopidogrel monotherapy for VTE prophylaxis after TJA increases transfusion risk by 69% (aOR 1.69) compared to aspirin without reducing DVT, PE, stroke, or MI rates.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study compared 90-day bleeding and thromboembolic outcomes in TJA patients receiving clopidogrel versus aspirin monotherapy for VTE prophylaxis using a national all-payer database (2016–2021) with 1:7 propensity-score matching. Clopidogrel was associated with significantly higher rates of transfusion (aOR 1.69, 95% CI 1.30–2.21) and acute anemia (aOR 1.13, 95% CI 1.03–1.26). No significant differences were found in DVT, PE, stroke, MI, hematoma, or hemorrhage between groups.
Key Limitation
Retrospective database design cannot distinguish patients continuing clopidogrel for mandatory cardiac indications (e.g., recent coronary stent) from those using it solely for VTE prophylaxis, potentially confounding the bleeding risk signal with underlying cardiovascular disease severity.
Original Abstract
BACKGROUND
Patients undergoing total joint arthroplasty (TJA) who are on long-term use of clopidogrel for atherothrombotic prophylaxis often continue this drug as venous thromboembolism (VTE) chemoprophylaxis following primary total knee (TKA) and total hip arthroplasty (THA). We sought to assess the 90-day bleeding and thromboembolic risk profiles of patients receiving clopidogrel monotherapy for postoperative VTE chemoprophylaxis compared with those receiving aspirin following TJA.
METHODS
Utilizing a national, all-payer health-care database that captures approximately 25% of all inpatient procedures in the U.S., we identified all adult patients who underwent primary elective TKA or THA between 2016 and 2021. Patients who received clopidogrel monotherapy for postoperative VTE chemoprophylaxis were propensity-score matched in an approximately 1:7 ratio to patients who received aspirin monotherapy on the basis of age, sex, procedure type, perioperative tranexamic acid administration, and known indications for clopidogrel administration. Primary outcomes included the 90-day risks of bleeding and thromboembolic complications.
RESULTS
A total of 21,273 patients who received aspirin were matched to 3,078 patients who received clopidogrel. After matching, there were no significant differences between the 2 cohorts with respect to patient demographics, comorbidities, rates of tranexamic acid administration, and hospital characteristics. After accounting for potential confounding variables, patients who received clopidogrel were at an increased risk for postoperative blood transfusion (adjusted odds ratio [aOR]: 1.69; 95% confidence interval [CI]: 1.30 to 2.21; p < 0.001) and acute anemia (aOR: 1.13; 95% CI: 1.03 to 1.26; p = 0.015) relative to patients receiving aspirin. No significant differences between the cohorts in the risk of deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, hematoma, or hemorrhage were found.
CONCLUSIONS
Patients who received clopidogrel monotherapy for postoperative VTE chemoprophylaxis had an increased risk of postoperative bleeding complications but a similar risk of thromboembolic complications following TJA compared with patients who received aspirin. These findings suggest that the decision to resume clopidogrel for postoperative thromboprophylaxis should balance the potent antiplatelet activity with the risk of bleeding complications in high-risk cardiovascular patients.
LEVEL OF EVIDENCE
Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.